Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric letermovir prophylaxis after allogeneic HSCT
jRCT2080225146Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of letermovir in cytomegalovirus disease (CMV), sponsored by Merck & Co. Primary endpoints: Pharmacokinetics of letermovir, Clinically significant CMV infection through Week 14 and 1 more. Started Mar 2020; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on jRCT2080225146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225146.